evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,678 questions · 4,859 findings · 283 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1,225 · 25.2%GRADE not reported 215 · 4.4%Very low 1,241 · 25.5%Low 1,210 · 24.9%Moderate 776 · 16%High 192 · 4%

Summary of findings table ‐ Rifaximin vs placebo or no intervention

Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with placebo/no intervention (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs placebo or no intervention

Hepatic encephalopathy · prevention and treatment of hepatic encephalopathy in people with cirrhosis

Summary of findings table ‐ Rifaximin probably leads to lower hepatic encephalopathy ‐ total number compared with placebo/no intervention (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs placebo or no intervention

Non‐serious adverse events ‐ total number of particiapnts · prevention and treatment of hepatic encephalopathy in people with cirrhosis

It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of particiapnts compared with placebo/no intervention (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs non‐absorbable disaccharide

Mortality ‐ total number · prevention and treatment of hepatic encephalopathy in people with cirrhosis

Summary of findings table ‐ Rifaximin showed no clear difference in mortality ‐ total number compared with non‐absorbable disaccharide (low certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs non‐absorbable disaccharide

Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with non‐absorbable disaccharide (low certainty).

1 finding from 1 review

Summary of findings table ‐ Phenytoin vs lorazepam

Proportion of infants who achieve seizure control after the first loading dose of ASM · neonates with clinically diagnosed seizures

It is very uncertain whether summary of findings table ‐ Phenytoin changes proportion of infants who achieve seizure control after the first… compared with lorazepam (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Phenytoin vs lorazepam

Proportion of infants who develop sedation or drowsiness · neonates with clinically diagnosed seizures

It is very uncertain whether summary of findings table ‐ Phenytoin changes proportion of infants who develop sedation or drowsiness compared with lorazepam (very low certainty).

1 finding from 1 review

Rituximab vs intravenous methylprednisolone

CAS improvement (decrease) by 2 or more points · thyroid‐associated ophthalmopathy

Summary of findings table ‐ Rituximab showed no clear difference in CAS improvement (decrease) by 2 or more points compared with intravenous methylprednisolone (low certainty).

1 finding from 1 review

Rituximab vs placebo

Proptosis improvement (decrease) by 2 mm or more · thyroid‐associated ophthalmopathy

It is very uncertain whether summary of findings table ‐ Rituximab changes proptosis improvement (decrease) by 2 mm or more compared with placebo (very low certainty).

1 finding from 1 review

Rituximab vs placebo

Adverse effects · thyroid‐associated ophthalmopathy

It is very uncertain whether summary of findings table ‐ Rituximab changes adverse effects compared with placebo (very low certainty).

1 finding from 1 review